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parallel with similar efforts in Europe, strategies need to be 
developed to protect commercial and pet rabbits.
Tracking the spread of RHDV2 in Australia, in com-
petition with existing field strains, highlights the value 
of Australia’s rabbits and their diseases as a model sys-
tem for emerging infectious diseases. The point releases 
of both myxoma virus and RHDV into large naive host 
populations represent a grand experiment in disease emer-
gence and evolution (10), which provides a unique op-
portunity to study the virulence evolution of emerging 
pathogens as well as their complex interactions with each 
other. It is notable that since the release of RHDV in Aus-
tralia in 1995, strains of 1 viral lineage dominate the viral 
population nationwide despite hundreds of deliberate re-
releases of the original virus strain for local rabbit control, 
which strongly suggests it has a major selective advantage 
(7). That RHDV2 appeared in a wild rabbit is therefore 
remarkable, particularly because Australian field strains 
were spreading simultaneously in the same area. Com-
paring the epidemiology of this strain in Australia to the 
epidemiology of its well-documented spread in Europe 
will provide valuable insights into RHDV epidemiology 
relevant to both continents.
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To the Editor: A traveler returning from the Middle 
East initiated an outbreak of Middle East respiratory syn-
drome (MERS) in South Korea in 2015, which resulted 
in 186 cases and 36 deaths (1–3). We report a case of 
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MERS in a 43-year-old man from South Korea who ac-
quired this disease during this outbreak (online Technical 
Appendix Figure 1, panel A, http://wwwnc.cdc.gov/EID/
article/21/12/15-1232-Techapp1.pdf) (4).
The National Health and Family Planning Commission 
of China determined that collection of data for this patient 
was part of a public health investigation of an emerging 
outbreak. Therefore, informed consent was not required. 
This study was approved by the ethical committee of the 
First Affiliated Hospital of Guangzhou Medical University.
The patient had been receiving thiamazole for 7 years 
for hyperthyroidism. He had contact with the index case-
patient during the outbreak in South Korea on May 16, 
2015. On May 25, the patient traveled to Hong Kong and 
then to Huizhou, China. He was hospitalized in China on 
May 28 (day 7 of illness). At admission, he had a high fever 
(temperature 39.5°C) and a dry cough. Chest radiography 
on day 7 showed mild bilateral ground glass opacities in the 
lower lung (online Technical Appendix Figure 1, panel B).
The patient was given oseltamivir (150 mg, 2×/day for 
2 days) until identified as being infected with Middle East 
respiratory syndrome coronavirus (MERS-CoV) on day 8 by 
real-time reverse transcription PCR. He was given ribavirin 
(2.0 mg on day 8; 0.6 mg 3×/d on days 9–16; and 0.6 mg 
2×/d on days 17–19) and 135 μg of peginterferon αa-2a by 
intravenous injection on day 8 (online Technical Appendix 
Table 2). Thrombocytopenia and a decrease in the hemoglo-
bin level developed, which might have been related to use of 
ribavirin (online Technical Appendix Table 1).
Chest radiography on June 1 (day 11) showed in-
creased bilateral consolidation of the patient’s lower lung 
(online Technical Appendix Figure 1, panel C). He was 
given intravenous immunoglobulin, antimicrobial drugs, 
and thymosin α1. His body temperature returned to nor-
mal on day 14 (online Technical Appendix Figure 2). Chest 
radiography on day 35 showed resolution of bilateral lung 
infiltrations (online Technical Appendix Figure 1, panel D). 
He was discharged on day 36.
Viral RNA was detected in sputum and fecal speci-
mens up to day 26 of illness. Virus load in sputum speci-
mens collected on days 11–15 were lower than in speci-
mens obtained on days 16–18 (online Technical Appendix 
Figure 3, panel A). Swab samples collected on days 13 and 
15 from the patient’s palm, mobile telephone, blanket, and 
bed railings, and from his hospital room floor were nega-
tive for viral RNA.
Concentrations of proinflammatory cytokines and 
chemokines (interferon-α, interferon-inducible protein 10, 
monocyte chemoattractant protein-1, interleukin 6 [IL-6], IL-
10, tumor necrosis factor-α, IL-8, macrophage inflammatory 
protein-α [MIP-1α], MIP-1β, and IL-1β) were determined for 
serial serum samples. Interferon-α, interferon-inducible pro-
tein 10, monokine induced by interferon-γ, IL-6, monocyte 
chemoattractant protein-1, and IL-8 were detected on day 11 
of illness but levels decreased as the patient clinically im-
proved (online Technical Appendix Figure 3, panel B).
The peginterferon αA2 the patient was given on day 8 
might have influenced his plasma interferon-α levels (6). 
However, a previous study also showed increased levels of 
interferon-α in a patient who survived MERS-CoV infec-
tion but not in a person who died of MERS (7). Although 
MERS-CoV evades induction of innate immune responses 
by cell types, the virus elicits interferon responses in plas-
macytoid dendritic cells in vitro (8). Levels of tumor ne-
crosis factor-α, MIP-1α, MIP-1β, IL-10, and IL-1β did not 
increase in any of these specimens.
Peripheral blood mononuclear cells (PBMCs) ob-
tained on day 24 of illness showed a strong specific T-cell 
response against MERS-CoV spike protein but not against 
severe acute respiratory syndrome coronavirus (SARS-CoV) 
spike protein (online Technical Appendix Figure 3, panel C). 
PBMCs from persons who were infected with SARS-CoV 
in 2003, as well as healthy persons, showed low-level T-cell 
responses against MERS-CoV spike protein, although some 
persons with a history of SARS still had detectable responses 
to SARS-CoV spike protein. It was reported that T-cell re-
sponses to SARS-CoV were directed against spike and nu-
cleocapsid proteins (9). We did not have sufficient PBMCs to 
test T-cell responses against nucleocapsid protein.
Results for MERS-CoV antibody were negative at 
day 11 of illness by MERS-CoV spike pseudotype as-
say (MERS-S ppNT), microneutralization, 50% plaque 
reduction neutralization test (PRNT50), and S1 ELISA 
(EUROIMMUN AG, Lübeck, Germany). The patient 
showed seroconversion by day 14. MERS-S ppNT and 
PRNT50 provided earlier evidence of seroconversion (day 
15) and higher antibody titers than the microneutralization, 
(day 18) (online Technical Appendix Figure 3, panel D). 
Potent T-cell responses were elicited to MERS-CoV spike 
protein. These responses did not show cross-reactivity with 
SARS-CoV spike protein.
The MERS-S ppNT, which does not require Biosafety 
Level 3 containment, had sensitivity equivalent with that of 
PRNT50, which requires containment. Thus, MERS-S ppNT 
is a sensitive and specific assay for detecting neutralizing an-
tibody against MERS-CoV. The sensitivity and specificity of 
this assay have been well-documented with serum samples 
from dromedary camels and other animals (10).
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